Spinal cord reactive-antibodies identified by serological antigen selection show prognostic value in traumatic spinal cord injury patients
Neurobiology of Disease · 2026
DOI: 10.1016/j.nbd.2026.107306 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurobiology of Disease, 2026. Verfasst von Astrid Pues und 19 weiteren Autor:innen. Beteiligte Einrichtung: UHasselt - Hasselt University, Faculty of Medicine and Life Sciences, Biomedical Research Institute, Department of Immunology and Infection, Hasselt,…. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Autoantibodies, Spinal Cord, Autoantigens. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wings for Life Privatstiftung für Rückenmarksforschung, Hasselt University, SpinalCure Australia.
Abstract (Originalsprache)
Outcome prediction after traumatic spinal cord injury (SCI) remains challenging due to patient heterogeneity, highlighting the need for better prognostic tools. Neural tissue damage and blood-spinal cord barrier disruption expose the immune system to spinal cord proteins, eliciting autoantibody responses that may be beneficial or detrimental. This study aimed to identify the (auto)antibody profile of SCI patients, and examine the prognostic antibody biomarker potential. A healthy and a SCI cDNA phage display library were screened for novel antibodies using SCI samples (n = 12/11). Antibody reactivity was validated using phage ELISA in 291 samples from 190 SCI patients collected at baseline (0-4 days post-injury [dpi]) and follow-up (15-30 dpi; 31-56 dpi). Correlations between antibody reactivity and clinical characteristics including SCI level, and American Spinal Injury Association impairment scale (AIS), were analysed. Immunofluorescent stainings were used to validate expression of two antigenic targets. We identified antibodies against 6 novel autoantigens (University Hasselt [UH.] SCI.104/105/106/108/109/110). A panel of three antigens (UH.SCI.104/109/110) demonstrated increased antibody reactivity in 31.3% of SCI patients with AIS improvement versus 4.8% with no improvement, resulting in a positive likelihood ratio of 6.56. Patients with injuries above thoracic level 4 had significantly lower antibody reactivity against UH.SCI.105/110 compared to patients with lower lesions. Anti-UH.SCI.108/110 antibodies bound to astrocytes, in mouse spinal cord tissue and primary cell cultures, confirming disease-relevant reactivity. Antibodies targeting the novel antigens demonstrated prognostic biomarker potential, supporting their future use in outcome prediction and patient stratification for SCI management and clinical trial design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UHasselt - Hasselt University, Faculty of Medicine and Life Sciences, Biomedical Research Institute, Department of Immunology and Infection, Hasselt, Belgium.
- UHasselt - Hasselt University, Faculty of Medicine and Life Sciences, Biomedical Research Institute, Department of Cardio and Organ systems, Hasselt, Belgium.
- Adelante Centre of Expertise in Rehabilitation and Audiology, Hoensbroek, the Netherlands; Maastricht University, Research School CAPHRI, Department of Rehabilitation Medicine, Maastricht, the Netherlands.
- Ziekenhuis Oost-Limburg, Department of Neurosurgery, Genk, Belgium.
- Algemeen Ziekenhuis Turnhout, Department of Neurosurgery, Turnhout, Belgium.
- University Hospitals Leuven, Neurosurgery, Leuven, Belgium.
Förderung
- Wings for Life Privatstiftung für Rückenmarksforschung
- Hasselt University
- SpinalCure Australia
- Research Foundation Flanders
Zitieren
APA
Pues, A., Vandormael, P., Vangansewinkel, T., Veeningen, N., Vanherle, S., van Laake-Geelen, C. C. M., Cornips, E. M. J., Peuskens, D., Buelens, E., Deckers, J., Depreitere, B., Bamps, S., Ruitenberg, M. J., Arevalo-Martin, A., Garcia-Ovejero, D., Grassner, L., Mach, O., Leister, I., Fraussen, J., & Somers, V. (2026). Spinal cord reactive-antibodies identified by serological antigen selection show prognostic value in traumatic spinal cord injury patients. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2026.107306
Vancouver
Pues A, Vandormael P, Vangansewinkel T, Veeningen N, Vanherle S, van Laake-Geelen CCM, et al. Spinal cord reactive-antibodies identified by serological antigen selection show prognostic value in traumatic spinal cord injury patients. Neurobiology of Disease. 2026. doi:10.1016/j.nbd.2026.107306
BibTeX
@article{Pues2026,
author = {Pues, Astrid and Vandormael, Patrick and Vangansewinkel, Tim and Veeningen, Naomi and Vanherle, Sam and van Laake-Geelen, Charlotte C M and Cornips, Erwin M J and Peuskens, Dieter and Buelens, Eveleen and Deckers, Jens and Depreitere, Bart and Bamps, Sven and Ruitenberg, Marc J and Arevalo-Martin, Angel and Garcia-Ovejero, Daniel and Grassner, Lukas and Mach, Orpheus and Leister, Iris and Fraussen, Judith and Somers, Veerle},
title = {Spinal cord reactive-antibodies identified by serological antigen selection show prognostic value in traumatic spinal cord injury patients},
journal = {Neurobiology of Disease},
year = {2026},
doi = {10.1016/j.nbd.2026.107306}
}
EUVIMED